EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node‐positive bladder cancer

Markus von Deimling, Marc Furrer iD, Laura S Mertens iD, Andrea Mari iD, Noor van Ginkel, Mara Bacchiani, Moritz Maas, Renate Pichler iD, Roger Li iD, Marco Moschini iD, Alberto Bianchi, Malte W Vetterlein und 19 weitere

BJU International · 2024-03 · 133 (3) · 341-350

DOI: 10.1111/bju.16210 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 15.11.2023. Verfasst von Markus von Deimling und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine the oncological impact of extended pelvic lymph node dissection (ePLND) vs standard PLND (sPLND) during radical cystectomy (RC) in clinically lymph node‐positive (cN+) bladder cancer (BCa). Patients and Methods In this retrospective, multicentre study we included 969 patients who underwent RC with sPLND (internal/external iliac and obturator lymph nodes) or ePLND (sPLND plus common iliac and presacral nodes) with or without platin‐based peri‐operative chemotherapy for cTany N1‐3 M0 BCa between 1991 and 2022. We assessed the impact of ePLND on recurrence‐free survival (RFS) and the distribution of recurrences (locoregional and distant recurrences). The secondary endpoint was overall survival (OS). We performed propensity‐score matching using covariates associated with the extent of PLND in univariable logistic regression analysis. The association of the extent of PLND with RFS and OS was investigated using Cox regression models.

Results

Of 969 cN+ patients, 510 were 1:1 matched on propensity scores. The median (interquartile range [IQR]) time to recurrence was 8 (4–16) months, and median (IQR) follow‐up of alive patients was 30 (13–51) months. Disease recurrence was observed in 104 patients in the ePLND and 107 in the sPLND group. Of these, 136 (27%), 47 (9.2%) and 19 patients (3.7%) experienced distant, locoregional, or both distant and locoregional disease recurrence, respectively. When stratified by the extent of PLND, we did not find a difference in recurrence patterns ( P > 0.05). ePLND improved neither RFS (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.70–1.19; P = 0.5) nor OS (HR 0.78, 95% CI 0.60–1.01; P = 0.06) compared to sPLND. Stratification by induction chemotherapy did not change outcomes.

Conclusion

Performing an ePLND at the time of RC in cN+ patients improved neither RFS nor OS compared to sPLND, regardless of induction chemotherapy status. Pretreatment risk stratification is paramount to identify ideal candidates for RC with ePLND as part of a multimodal treatment approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalUrinary Bladder NeoplasmsHumansRetrospective StudiesLymph Node ExcisionLymph NodesCystectomy

Stichwörter der Autor:innen

cN+induction chemotherapylymph node-positiveradical cystectomytemplateurinary bladder neoplasmsurothelial cancer

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland.
  • Department of Urology, Solothurner Spitäler AG, Olten, Solothurn, Switzerland.
  • Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy.

ORCID-Profile: Marc Furrer, Laura S Mertens, Andrea Mari, Renate Pichler, Roger Li, Marco Moschini, Chiara Lonati, Karl H Tully, Luca Afferi, Francesco Soria, Francesco Del Giudice, Ekaterina Laukhtina, Alessandro Antonelli, Yair Lotan, Bernhard Kiss

Zitieren

APA

von Deimling, M., Furrer, M., Mertens, L. S., Mari, A., van Ginkel, N., Bacchiani, M., Maas, M., Pichler, R., Li, R., Moschini, M., Bianchi, A., Vetterlein, M. W., Lonati, C., Crocetto, F., Taylor, J., Tully, K. H., Afferi, L., Soria, F., Del Giudice, F., …, & CLIPOLY Study Group Collaborators (2024). Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node‐positive bladder cancer. BJU International, 133(3), 341-350. https://doi.org/10.1111/bju.16210

Vancouver

von Deimling M, Furrer M, Mertens LS, Mari A, van Ginkel N, Bacchiani M, et al. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node‐positive bladder cancer. BJU International. 2024;133(3):341-350. doi:10.1111/bju.16210

BibTeX
@article{vonDeimling2024,
  author = {von Deimling, Markus and Furrer, Marc and Mertens, Laura S and Mari, Andrea and van Ginkel, Noor and Bacchiani, Mara and Maas, Moritz and Pichler, Renate and Li, Roger and Moschini, Marco and Bianchi, Alberto and Vetterlein, Malte W and Lonati, Chiara and Crocetto, Felice and Taylor, Jacob and Tully, Karl H and Afferi, Luca and Soria, Francesco and Del Giudice, Francesco and Longoni, Mattia and Laukhtina, Ekaterina and Antonelli, Alessandro and Rink, Michael and Fisch, Margit and Lotan, Yair and Spiess, Philippe E and Black, Peter C and Kiss, Bernhard and Pradere, Benjamin and Shariat, Shahrokh F and CLIPOLY Study Group Collaborators, CLIPOLY Study Group Collaborators},
  title = {Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node‐positive bladder cancer},
  journal = {BJU International},
  year = {2024},
  volume = {133},
  number = {3},
  pages = {341--350},
  doi = {10.1111/bju.16210}
}
Kostenlos starten →